BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/20/2017 12:50:09 PM | Browse: 128 | Download: 364
Publication Name World Journal of Hepatology
Manuscript ID 33223
Country of Manuscript Source United Kingdom
2017-02-07 18:42
Peer-Review Started
2017-02-13 14:37
To Make the First Decision
2017-03-08 09:41
Return for Revision
2017-03-10 17:22
2017-04-26 04:48
Second Decision
2017-05-07 16:02
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2017-05-15 05:47
Articles in Press
2017-05-15 05:47
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2017-06-02 07:41
Publish the Manuscript Online
2017-06-20 12:50
ISSN 1948-5182 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript Type Review
Article Title Systemic treatment of hepatocellular carcinoma: Past, present and future
Manuscript Source Invited Manuscript
All Author List Esther Una Cidon
Funding Agency and Grant Number
Correspondence To Esther Una Cidon, MD, PhD, Medical Oncologist, Department of Medical Oncology, Royal Bournemouth Hospital, Castle Lane East, Castle Ln E, BH7 7DW Bournemouth, United Kingdom. esther.unacidon@rbch.nhs.uk
Keywords Hepatocellular carcinoma; Alphafetoprotein; Sorafenib; Nivolumab; MEK
Core Tip The incidence of hepatocellular carcinoma (HCC) is rising in Western countries due to hepatitis C. Unfortunately, 40% of patients present with advanced disease which is only amenable for palliative systemic treatment. The development of effective therapies for HCC is a challenge, due partly to its inherent chemo­resistance, the pharmacologic challenges due to an ill liver, etc. Although some responses to traditional chemo­therapy have been reported, the multikinase inhibitor sorafenib has shown survival benefit in advanced HCC with preserved liver function. Recently immunotherapy seems to be a promising approach for some patients.
Publish Date 2017-06-20 12:50
Citation Cidon EU. Systemic treatment of hepatocellular carcinoma: Past, present and future. World J Hepatol 2017; 9(18): 797-807
Url http://www.wjgnet.com/1948-5182/full/v9/i18/797.htm
DOI http://dx.doi.org/10.4254/wjh.v9.i18.797
Full Article (PDF) WJH-9-797.pdf
Full Article (Word) WJH-9-797.doc
Revised Manuscript 33223-Review.docx
Peer-review Report 33223-Peer-review(s).pdf
Answering Reviewers 33223-Answering reviewers.pdf
Scientific Misconduct Check 33223-Scientific misconduct check.pdf
Scientific Editor Work List 33223-Scientific editor work list.pdf
Audio Core Tip 33223-Audio core tip.aiff
Conflict-of-Interest Disclosure Form 33223-Conflict-of-interest statement.pdf
Copyright License Agreement 33223-Copyright assignment.pdf